Recent Updates
Recently added Catalysts
GOSS Positive Sentiment

Seralutinib exhibits anti-fibrotic effects in human models of pulmonary fibrosis: an emerging option for group 1 and 3 pulmonary hypertension?

Tuesday, October 15, 2024 BiopharmaWatch Research 2 min read
Add on Google
Key Takeaway: The article discusses Seralutinib's anti-fibrotic effects observed in human models of pulmonary fibrosis. It highlights the drug's potential as a treatment option for patients with group 1 and 3 pulmonary hypertension. The findings suggest that Seralutinib may offer new hope in managing these conditions.
Price reaction · baseline $0.9705 (2024-10-15T16:37:00.000Z) · hit during market hours · clean, no other GOSS news in the window
day 0 close · peak
-0.3%

Market Sentiment Analysis

POSITIVE FACTORS

  • Seralutinib shows promising anti-fibrotic effects.
  • Potential treatment option for pulmonary hypertension.
  • Emerging data supports its use in clinical settings.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+53%
120-day peak, hindsight
Typical move
5.9%
average across 2 past catalysts
Cash runway
~4 mo
High dilution risk
Lead asset
GB001
Phase 2 · Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP)

Full Press Release Details

Seralutinib exhibits anti-fibrotic effects in human models of pulmonary fibrosis: an emerging option for group 1 and 3 pulmonary hypertension?
• About Overview Team Management Board of Directors Collaboration Contact Locations Contact Form Sponsorship Disclosure
• Seralutinib About Seralutinib PAH PH-ILD Posters & Presentations
• Patients Overview Expanded Access
• Investors Overview News Events & Presentations Events Presentations Filings Governance Overview Committee Composition Management Board of Directors Stock Stock Quote & Chart Historical Price Lookup Investment Calculator Analyst Coverage Info FAQs Contact IR Email Alerts
• Careers & Culture Who We Are Open Positions
• Overview
• Team
• Management
• Board of Directors
• Collaboration
• Contact
• Locations
• Contact Form
• Sponsorship Disclosure
• About Seralutinib
• PAH
• PH-ILD
• Posters & Presentations
• Overview
• Expanded Access
• Overview
• News
• Events & Presentations Events Presentations
• Filings
• Governance Overview Committee Composition Management Board of Directors
• Stock Stock Quote & Chart Historical Price Lookup Investment Calculator Analyst Coverage
• Info FAQs Contact IR Email Alerts
• Events
• Presentations
• Overview
• Committee Composition
• Management
• Board of Directors
• Stock Quote & Chart
• Historical Price Lookup
• Investment Calculator
• Analyst Coverage
• FAQs
• Contact IR
• Email Alerts
• Who We Are
• Open Positions

Frequently Asked Questions

What is Seralutinib?

Seralutinib is a drug being studied for its anti-fibrotic effects in pulmonary fibrosis.

What conditions could Seralutinib treat?

It may be an option for patients with group 1 and 3 pulmonary hypertension.

What are the effects of Seralutinib?

It exhibits promising anti-fibrotic effects in human models.

ShareAdd on Google
Tags: GOSS Viatris Investor Conferences Healthcare Seralutinib pulmonary fibrosis pulmonary hypertension anti-fibrotic
Last updated: Oct 15, 2024

Biotech snapshot

Cash runway
$57M liquidity · $13M/mo burn
~4 mo
High dilution risk
Lead asset
GB001Phase 2
Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP) →

Catalyst track record

+53%
best trade around GOSS's most recent catalyst

Peak hindsight return over a 120-day window, across 2 tracked FDA/PDUFA catalysts for GOSS.

See every catalyst's timing & PoA →